Visible Light Promoted Site-Specific Functionalization of α-Acyloxy Carboxamides: Unlocking a Forbidden Chemical Space in the Passerini Reaction
Brunelli F, Quartieri F, Miletto I, Pulici M, Papeo G, Tron GC Chemistry (2024), 5;30(50), e202402175
Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors
Cervi G, D’Alessio R, Bindi S, Buffa L, Burocchi A, Canevari G, Modugno M, Motto I, Saturno G, Orsini P Eur J Med Chem (2024), 270, 116375
Photocatalytic radical coupling of organoborates with α-Halogenated electron-poor olefins
Caldarelli M, Rezzi SJ, Colombo N, Pirali T, Papeo G J Org Chem (2024), 5, 89(1), 633-643
A novel platform of diversified cytotoxins and targeted payloads to drive ADC innovation
P. Orsini, M. Salsa, S. Rizzi, U. Cucchi, D. Faiardi, A. Burocchi, A. Ciavolella, R. Lupi, F. Gasparri, B. Valsasina AACR Annual Meeting 2024; April 5-10, 2024; San Diego –Abstract 5805 Cancer Res (2024) 84 (6_Supplement)
The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer
G. Texido, F. Gasparri, A. Ciavolella, L. Gianellini, A. Burocchi, I. Fraietta, A.E. Pedersen, A. Ocaña, R. Colombo, D. Roberti, L. Mahnke, C. Perrera AACR Annual Meeting 2024; April 5-10, 2024; San Diego –Abstract 509 Cancer Res (2024) 84 (6_Supplement)
Development of 14-amino-anthracyclines as novel payloads for ADC production showing potent anti-tumor activity and improved safety profile
P. Orsini, M. Salsa, A. Burocchi, A. Ciavolella, U. Cucchi, D. Faiardi, S. Rizzi, F. Gasparri, B. Valsasina 38th National Medicinal Chemistry Symposium; June 23-26, 2024; Seattle, WA.
A payload-linker generating machine to quickly move from small molecules to characterized tool ADCs and PDCs
R. Lupi, P. Orsini, M. Salsa, S. Rizzi, U. Cucchi, D. Faiardi, A. Burocchi, A. Ciavolella, F. Gasparri, B. Valsasina 14th World ADC London 2024; March 12-15, 2024; London, UK
Discovery of NMS-0963, a potent, selective and orally available Syk inhibitor with outstanding preclinical activity in diffuse large B-cell lymphoma
L. Buffa, G. Cervi, R. D’Alessio, S. Bindi, A. Burocchi, G. Canevari, M. Modugno, I. Motto, G. Saturno, P. Orsini 58th International Conference on Medicinal Chemistry (RICT 2024); July 3-5, 2024; Bordeaux, France
Photocatalytic Giese reaction of boron-containing compounds with α-Halogenated electron-poor olefins
M. Caldarelli, S.J. Rezzi, N. Colombo, T.Pirali, G. Papeo EFMC-ISMC 2024; XXVIII EFMC International Symposium on Medicinal Chemistry; September 1-5, 2024; Rome, Italy –Abstract P411
Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR) The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2. NMS […]
